Moxham Christopher 4
4 · Fulcrum Therapeutics, Inc. · Filed Feb 10, 2021
Insider Transaction Report
Form 4
Moxham Christopher
Chief Scientific Officer
Transactions
- Award
Stock Option (right to buy)
2021-02-08+100,000→ 100,000 totalExercise: $12.60Exp: 2031-02-07→ Common Stock (100,000 underlying)
Footnotes (1)
- [F1]This option was granted on February 8, 2021 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of February 6, 2021, subject to continued service.